CDMO European Landscape in 2025

Updated  new infographic summarises the main CDMO players operating facilities in Europe. 

The global market for BioPharma Contract Development & Manufacturing (CDMO) is forecast to keep expanding at a high growth rate.

The European CDMO market is projected to grow at a CAGR of approximately 7-8% according to various reports.

• Precedence Research values the overall European CDMO market at USD $42.6 Billion in 2024, approximated 23% of the global market. European CDMOs are projected to surpass USD $88.8 Billion revenue by 2034, expanding at a CAGR of 7.7% from 2024 to 2034.  
  
  
• Grand View Research highlights the varying growth of different modalities with Small Molecule CDMOs representing $16.1 Billion USD in 2024 and growing at 7.5% CAGR, while Large Molecule drug substance represented $3.8 Billion in 2023, with a higher growth rate of 8.8% CAGR.

This infographic summarises the main players with facilities in Europe who develop and manufacture Small Molecule, Biologics and Cell & Gene therapy drug products and formulation.

Download your high resolution infographic by filling out the short form.

Note: Due to the high number of Small Molecule manufacturers in Europe, we have only included CDMOs with in this category with more than one facility.

Who are we missing?

While every effort has been made to capture all contract manufacturers in the infographic, we are not yet comprehensive.

• Add your company by completing this short form so we can verify your inclusion